The company posted a consolidated net profit of ₹129.2 crore for Q4FY26, up 51% from ₹86 crore in the corresponding quarter last year. Revenue rose 11.2% year-on-year to ₹1,323.4 crore from ₹1,190.3 crore.
EBITDA increased 10% to ₹239.6 crore compared with ₹218 crore a year ago, while EBITDA margin came in marginally lower at 18% versus 18.3% in the year-ago period.
Following the earnings announcement, shares of Strides Pharma Sciences gained over 4% intraday to hit ₹1,198.80 on the NSE before paring gains to trade largely flat at ₹1,158.20 in afternoon trade.
The board recommended a final dividend of ₹5 per equity share of face value ₹10 each for FY26. The company said the record date for determining eligible shareholders will be announced later, while the dividend will be paid within 30 days of shareholder approval at the upcoming AGM.
For the full year, the company’s US market revenue stood at ₹2,489.7 crore, growing 2% year-on-year, while Ex-US market revenue rose sharply by 21% to ₹2,240.4 crore, emerging as the key growth driver for the business.
Net debt stood at ₹1,436.5 crore at the end of FY26, impacted by foreign exchange depreciation. However, the net debt-to-EBITDA ratio improved to 1.55x from 1.9x in FY25.
Also Read: VRL Logistics Q4 profit slips 3% despite higher revenue; margin contracts
Managing Director and Group CEO Badree Komandur said the company delivered strong profitability and efficiency metrics during FY26, led by robust momentum in Ex-US markets. He added that operational PAT and EPS rose 50% year-on-year, reflecting operating leverage, while the US business remained stable despite a weaker flu season in the second half.
The company also said it remains focused on delivering long-term sustainable and profitable growth despite geopolitical uncertainties and a challenging external environment.
